Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association

키워드

참고문헌 (124)

1. Yamada R, "Hepatic artery embolization in 32 patients with unresectable hepatoma", Osaka City Med J, 26, pp.81~96 (1980)
2. Yamada R, "Hepatic artery embolization in 120 patients with unresectable hepatoma", Radiology, 148, pp.397~401 (1983)
3. Ohishi H, "Transcatheter arterial embolization using iodized oil(lipiodol)mixed with an anticancer drug for the treatment of hepatocellular carcinoma", Cancer Chemother Pharmacol, 23(Suppl), pp.S33~S36 (1989)
4. Varela M, "Chemoembolization of hepatocellular carcinoma with drug eluting beads : efficacy and doxorubicin pharmacokinetics", J Hepatol, 46, pp.474~481 (2007)
5. Llovet JM, "Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma : a randomised controlled trial", Lancet, 359, pp.1734~1739 (2002)
6. Lo CM, "Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma", Hepatology, 35, pp.1164~1171 (2002)
7. Takayasu K, "Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients", Gastroenterology, 131, pp.461~469 (2006)
8. Takayasu K, "Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines", J Hepatol, 56, pp.886~892 (2012)
9. Lencioni R, "Lipiodol transarterial chemoembolization for hepatocellular carcinoma : a systematic review of efficacy and safety data", Hepatology, 64, pp.106~116 (2016)
10. Park JW, "Global patterns of hepatocellular carcinoma management from diagnosis to death : the BRIDGE Study", Liver Int, 35, pp.2155~2166 (2015)
11. Kim BK, "Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period : a nationwide random sample study", PLoS One, 14, pp.e0223678~ (2019)
12. Korean Liver Cancer Association (KLCA), "2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma", Korean Journal of Radiology, 23(12), pp.1126~1240 (2022), 대한영상의학회[DOI]
13. Korean Liver Cancer Association (KLCA), "2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma", Clinical and Molecular Hepatology, 28(4), pp.583~705 (2022), 대한간학회
14. Korean Liver Cancer Association (KLCA), "2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma", Journal of Liver Cancer, 23(1), pp.1~120 (2023), 대한간암학회[DOI]
15. Omata M, "Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma : a 2017 update", Hepatol Int, 11, pp.317~370 (2017)
16. Reig M, "BCLC strategy for prognosis prediction and treatment recommendation : the 2022 update", J Hepatol, 76, pp.681~693 (2022)
17. Kuo TM, "Why cannot BCLC 0-or A-stage patients receive curative treatment?", Gastrointest Tumors, 7, pp.125~133 (2020)
18. Choi JW, "Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus", Eur Radiol, 27, pp.1448~1458 (2017)
19. Chan AO, "A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma", Cancer, 94, pp.1747~1752 (2002)
20. Chung JW, "Hepatic tumors : predisposing factors for complications of transcatheter oily chemoembolization", Radiology, 198, pp.33~40 (1996)
21. 최태원, "The Safety and Clinical Outcomes of Chemoembolization in Child-Pugh Class C Patients with Hepatocellular Carcinomas", Korean Journal of Radiology, 16(6), pp.1283~1293 (2015), 대한영상의학회[DOI]
22. Song SY, "Liver abscess after transcatheter oily chemoembolization for hepatic tumors : incidence, predisposing factors, and clinical outcome", J Vasc Interv Radiol, 12, pp.313~320 (2001)
23. Woo S, "Liver abscess after transarterial chemoembolization in patients with bilioenteric anastomosis : frequency and risk factors", AJR Am J Roentgenol, 200, pp.1370~1377 (2013)
24. Kim W, "Risk factors for liver abscess formation after hepatic chemoembolization", J Vasc Interv Radiol, 12, pp.965~968 (2001)
25. de Baere T, "Treatment of liver tumors with lipiodol TACE : technical recommendations from experts opinion", Cardiovasc Intervent Radiol, 39, pp.334~343 (2016)
26. Li B, "Prophylactic use of antibiotics for postsurgical infection in c-TACE and DEB-TACE high-risk patients : a case-control study", J Healthc Eng, 2022, pp.6203817~ (2022)
27. Chen J, "Retrospective analysis of Chinese patients with hepatocellular carcinoma(HCC)undergoing transcatheter arterial chemoembolization(TACE)with or without prophylactic antibiotic therapy", J Coll Physicians Surg Pak, 28, pp.914~918 (2018)
28. Yoshihara S, "Association between prophylactic antibiotic use for transarterial chemoembolization and occurrence of liver abscess : a retrospective cohort study", Clin Microbiol Infect, 27, pp.1514~ (2021)
29. Khan W, "Moxifloxacin prophylaxis for chemoembolization or embolization in patients with previous biliary interventions : a pilot study", AJR Am J Roentgenol, 197, pp.W343~W345 (2011)
30. Patel S, "Effectiveness of an aggressive antibiotic regimen for chemoembolization in patients with previous biliary intervention", J Vasc Interv Radiol, 17, pp.1931~1934 (2006)
31. Ebisutani C, "Antibiotic prophylaxis in transcatheter treatment of hepatocellular carcinoma : an open randomized prospective study of oral versus intravenous administration", Intern Med, 49, pp.1059~1065 (2010)
32. Leung DA, "Determinants of postembolization syndrome after hepatic chemoembolization", J Vasc Interv Radiol, 12, pp.321~326 (2001)
33. Yang H, "Dexamethasone prophylaxis to alleviate postembolization syndrome after transarterial chemoembolization for hepatocellular carcinoma : a randomized, double-blinded, placebocontrolled study", J Vasc Interv Radiol, 28, pp.1503~1511 (2017)
34. Sainamthip P, "Single dose dexamethasone prophylaxis of postembolisation syndrome after chemoembolisation in hepatocellular carcinoma patient : a randomised, double-blind, placebocontrolled study", World J Clin Cases, 9, pp.9059~9069 (2021)
35. Ogasawara S, "A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization", Hepatology, 67, pp.575~585 (2018)
36. Lyu N, "Effect and safety of prophylactic parecoxib for pain control of transarterial chemoembolization in liver cancer : a single-center, parallel-group, randomized trial", J Am Coll Radiol, 19(1 Pt A), pp.61~70 (2022)
37. Lv N, "Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma : a prospective randomized trial", Eur Radiol, 26, pp.3492~3499 (2016)
38. Gentilini P, "Cirrhosis, renal function and NSAIDs", J Hepatol, 19, pp.200~203 (1993)
39. Park CM, "Celiac axis stenosis : incidence and etiologies in asymptomatic individuals", Korean J Radiol, 2, pp.8~13 (2001)
40. Song SY, "Celiac axis and common hepatic artery variations in 5002 patients : systematic analysis with spiral CT and DSA", Radiology, 255, pp.278~288 (2010)
41. Choi TW, "Anatomic variations of the hepatic artery in 5625 patients", Radiol Cardiothorac Imaging, 3, pp.e210007~ (2021)
42. Kwon JW, "Transcatheter arterial chemoembolization for hepatocellular carcinomas in patients with celiac axis occlusion", J Vasc Interv Radiol, 13, pp.689~694 (2002)
43. Moustafa AS, "Chemoembolization of hepatocellular carcinoma with extrahepatic collateral blood supply : anatomic and technical considerations", Radiographics, 37, pp.963~977 (2017)
44. Kim HC, "Recognizing extrahepatic collateral vessels that supply hepatocellular carcinoma to avoid complications of transcatheter arterial chemoembolization", Radiographics, 25(Suppl 1), pp.S25~S39 (2005)
45. 정진욱, "Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma: Prevalence and Causative Factors of Extrahepatic Collateral Arteries in 479 Patients", Korean Journal of Radiology, 7(4), pp.257~266 (2006), 대한영상의학회
46. Yoshida K, "Isolated arteries originating from the intrahepatic arteries : anatomy, function, and importance in intervention", J Vasc Interv Radiol, 29, pp.531~537 (2018)
47. Song SY, "Nonhepatic arteries originating from the hepatic arteries : angiographic analysis in 250patients", J Vasc Interv Radiol, 17, pp.461~469 (2006)
48. Kalender WA, "Flat-detector computed tomography(FD-CT)", Eur Radiol, 17, pp.2767~2779 (2007)
49. Virmani S, "Effect of C-arm angiographic CT on transcatheter arterial chemoembolization of liver tumors", J Vasc Interv Radiol, 18, pp.1305~1309 (2007)
50. de Baere T, "Initiative on superselective conventional transarterial chemoembolization results(INSPIRE)", Cardiovasc Intervent Radiol, 45, pp.1430~1440 (2022)
51. Lee IJ, "Conebeam computed tomography(CBCT)hepatic arteriography in chemoembolization for hepatocellular carcinoma : performance depicting tumors and tumor feeders", Cardiovasc Intervent Radiol, 38, pp.1218~1230 (2015)
52. In Joon Lee, "Conventional Chemoembolization for Hepatocellular Carcinoma: Role of Cone-Beam Computed Tomography Guidance", Journal of Liver Cancer, 19(1), pp.19~29 (2019), 대한간암학회[DOI]
53. Miyayama S, "Comparison of local control in transcatheter arterial chemoembolization of hepatocellular carcinoma ≤6 cm with or without intraprocedural monitoring of the embolized area using cone-beam computed tomography", Cardiovasc Intervent Radiol, 37, pp.388~395 (2014)
54. Wattanasatesiri T, "Cone-beam CT-guided chemoembolization in patients with complete response after previous chemoembolization but subsequent elevated α-fetoprotein without overt hepatocellular carcinoma", J Vasc Interv Radiol, 30, pp.1273~1280 (2019)
55. Iwazawa J, "Survival after C-arm CT-assisted chemoembolization of unresectable hepatocellular carcinoma", Eur J Radiol, 81, pp.3985~3992 (2012)
56. Lee IJ, "Conebeam CT hepatic arteriography in chemoembolization for hepatocellular carcinoma : angiographic image quality and its determining factors", J Vasc Interv Radiol, 25, pp.1369~1379 (2014)
57. Kothary N, "Imaging guidance with C-arm CT : prospective evaluation of its impact on patient radiation exposure during transhepatic arterial chemoembolization", J Vasc Interv Radiol, 22, pp.1535~1543 (2011)
58. Matsuo N, "Segmental transcatheter hepatic artery chemoembolization with iodized oil for hepatocellular carcinoma : antitumor effect and influence on normal tissue", J Vasc Interv Radiol, 4, pp.543~549 (1993)
59. Matsui O, "Small hepatocellular carcinoma : treatment with subsegmental transcatheter arterial embolization", Radiology, 188, pp.79~83 (1993)
60. Miyayama S, "Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas : relationship between local tumor recurrence and visualization of the portal vein with iodized oil", J Vasc Interv Radiol, 18, pp.365~376 (2007)
61. Golfieri R, "Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small(<5 cm)hepatocellular carcinomas", Hepatology, 53, pp.1580~1589 (2011)
62. Yamakado K, "Hepatic arterial embolization for unresectable hepatocellular carcinomas : do technical factors affect prognosis?", Jpn J Radiol, 30, pp.560~566 (2012)
63. Arizumi T, "Validation of a modified substaging system(Kinki Criteria)for patients with intermediate-stage hepatocellular carcinoma", Oncology, 89(Suppl 2), pp.47~52 (2015)
64. Yasui Y, "Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization", Hepatol Res, 48, pp.442~450 (2018)
65. Molgaard CP, "Intraarterial administration of lidocaine for analgesia in hepatic chemoembolization", J Vasc Interv Radiol, 1, pp.81~85 (1990)
66. Lee SH, "Intraarterial lidocaine administration for relief of pain resulting from transarterial chemoembolization of hepatocellular carcinoma : its effectiveness and optimal timing of administration", Cardiovasc Intervent Radiol, 24, pp.368~371 (2001)
67. Benzakoun J, "Risks factors for severe pain after selective liver transarterial chemoembolization", Liver Int, 37, pp.583~591 (2017)
68. Liu YS, "Nitroglycerine use in transcatheter arterial(chemo)embolization in patients with hepatocellular carcinoma : five-year retrospective study", Clin Res Hepatol Gastroenterol, 42, pp.542~552 (2018)
69. Katsanos K, "Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma : a network meta-analysis of randomized controlled trials", PLoS One, 12, pp.e0184597~ (2017)
70. Ikeda M, "Conventional or drug-eluting beads? Randomized controlled study of chemoembolization for hepatocellular carcinoma : JIVROSG-1302", Liver Cancer, 11, pp.440~450 (2022)
71. Lee IJ, "Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients", Ther Adv Med Oncol, 11, pp.1758835919866072~ (2019)
72. Chung JW, "Pulmonary oil embolism after transcatheter oily chemoembolization of hepatocellular carcinoma", Radiology, 187, pp.689~693 (1993)
73. Deschamps F, "Parameters for stable water-in-oil lipiodol emulsion for liver trans-arterial chemo-eembolization", Cardiovasc Intervent Radiol, 40, pp.1927~1932 (2017)
74. He MK, "Comparison of stable and unstable ethiodized oil emulsions for transarterial chemoembolization of hepatocellular carcinoma : results of a single-center double-blind prospective randomized controlled trial", J Vasc Interv Radiol, 29, pp.1068~1077 (2018)
75. Choi JW, "Comparison of drug release and pharmacokinetics after transarterial chemoembolization using diverse lipiodol emulsions and drug-eluting beads", PLoS One, 9, pp.e115898~ (2014)
76. Craig P, "Current trends in the treatment of hepatocellular carcinoma with transarterial embolization : variability in technical aspects", Cardiovasc Intervent Radiol, 42, pp.1322~1328 (2019)
77. Boulin M, "Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile : proof of concept using idarubicin", Eur Radiol, 26, pp.601~609 (2016)
78. Roth GS, "Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma", World J Gastroenterol, 26, pp.324~334 (2020)
79. Yoon HM, "Modified cisplatin-based transcatheter arterial chemoembolization for large hepatocellular carcinoma : multivariate analysis of predictive factors for tumor response and survival in a 163-patient cohort", J Vasc Interv Radiol, 24, pp.1639~1646 (2013)
80. Yoon SM, "Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion : a randomized clinical trial", JAMA Oncol, 4, pp.661~669 (2018)
81. Chung GE, "Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival", Radiology, 258, pp.627~634 (2011)
82. Kim HC, "Transarterial chemoembolization with additional cisplatin infusion for hepatocellular carcinoma invading the hepatic vein", J Vasc Interv Radiol, 24, pp.274~283 (2013)
83. Takayasu K, "Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma : propensity score analysis", AJR Am J Roentgenol, 194, pp.830~837 (2010)
84. Takayasu K, "Hepatocellular carcinoma : treatment with intraarterial iodized oil with and without chemotherapeutic agents", Radiology, 163, pp.345~351 (1987)
85. Clouse ME, "Chemoembolization for hepatocellular carcinoma : epinephrine followed by a doxorubicin-ethiodized oil emulsion and gelatin sponge powder", J Vasc Interv Radiol, 4, pp.717~725 (1993)
86. Louail B, "A new porcine sponge material for temporary embolization : an experimental short-term pilot study in swine", Cardiovasc Intervent Radiol, 29, pp.826~831 (2006)
87. Miyayama S, "Histopathological findings after ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma", Hepatol Res, 39, pp.374~381 (2009)
88. Sacco R, "Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma", J Vasc Interv Radiol, 22, pp.1545~1552 (2011)
89. Lammer J, "Prospective randomized study of doxorubicin-elutingbead embolization in the treatment of hepatocellular carcinoma : results of the PRECISION V study", Cardiovasc Intervent Radiol, 33, pp.41~52 (2010)
90. Golfieri R, "Randomised controlled trial of doxorubicineluting beads vs conventional chemoembolisation for hepatocellular carcinoma", Br J Cancer, 111, pp.255~264 (2014)
91. Monier A, "Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma : comparison between drugeluting beads and lipiodol emulsion", Eur Radiol, 27, pp.1431~1439 (2017)
92. Lee Myungsu, "Prospective Multi-Center Korean Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolics for Nodular Hepatocellular Carcinoma: A Two-Year Outcome Analysis", Korean Journal of Radiology, 22(10), pp.1658~1670 (2021), 대한영상의학회[DOI]
93. Spreafico C, "Transarterial chemoembolization for hepatocellular carcinoma with a new generation of beads : clinicalradiological outcomes and safety profile", Cardiovasc Intervent Radiol, 38, pp.129~134 (2015)
94. Prajapati HJ, "Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC", AJR Am J Roentgenol, 203, pp.W706~W714 (2014)
95. Deipolyi AR, "Safety and efficacy of 70-150 mum and 100-300 mum drugeluting bead transarterial chemoembolization for hepatocellular carcinoma", J Vasc Interv Radiol, 26, pp.516~522 (2015)
96. Urbano J, "Multicentre prospective study of drug-eluting bead chemoembolisation safety using tightly calibrated small microspheres in non-resectable hepatocellular carcinoma", Eur J Radiol, 126, pp.108966~ (2020)
97. Irie T, "Diameter of main tumor feeding artery of a hepatocellular carcinoma : Measurement at the entry site into the nodule", Hepatol Res, 46, pp.E100~E104 (2016)
98. Lee KH, "Distribution of iron oxide-containing Embosphere particles after transcatheter arterial embolization in an animal model of liver cancer : evaluation with MR imaging and implication for therapy", J Vasc Interv Radiol, 19, pp.1490~1496 (2008)
99. Malagari K, "Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma", Cardiovasc Intervent Radiol, 33, pp.541~551 (2010)
100. Brown KT, "Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone", J Clin Oncol, 34, pp.2046~2053 (2016)
101. Aliberti C, "Transarterial chemoembolization with small drugeluting beads in patients with hepatocellular carcinoma : experience from a cohort of 421 patients at an Italian center", J Vasc Interv Radiol, 28, pp.1495~1502 (2017)
102. Lencioni R, "Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded DC bead(DEBDOX) : technical recommendations", Cardiovasc Intervent Radiol, 35, pp.980~985 (2012)
103. Seki A, "Management of vascular lake phenomenon on angiography during chemoembolization with superabsorbent polymer microspheres", Jpn J Radiol, 33, pp.741~748 (2015)
104. Li H, "Occurrence, related factors and prognostic value of vascular lake in hepatocellular carcinoma patients treated with drug-eluting bead transarterial chemoembolization", Onco Targets Ther, 14, pp.4659~4670 (2021)
105. Kong J, "Clinical management of vascular lake during transarterial chemoembolization with CalliSpheres drug-eluting beads(DEBs)for the treatment of hepatocellular carcinoma", Transl Cancer Res, 9, pp.2895~2903 (2020)
106. Chang PY, "Multidisciplinary Taiwan consensus recommendations for the use of DEBDOX-TACE in hepatocellular carcinoma treatment", Liver Cancer, 7, pp.312~322 (2018)
107. Guiu B, "Liver", biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma : lipiodol vs. drugeluting beads, 2012, pp.56, 609~617
108. Malagari K, "Safety profile of sequential transcatheter chemoembolization with DC Bead(TM) : results of 237hepatocellular carcinoma(HCC)patients", Cardiovasc Intervent Radiol, 34, pp.774~785 (2011)
109. Piscaglia F, "Patient selection for transarterial chemoembolization in hepatocellular carcinoma : importance of benefit", risk assessment, 2018, pp.7, 104~119
110. Gaba RC, "Quality improvement guidelines for transarterial chemoembolization and embolization of hepatic malignancy", J Vasc Interv Radiol, 28, pp.1210~1223 (2017)
111. Miyayama S, "Main bile duct stricture occurring after transcatheter arterial chemoembolization for hepatocellular carcinoma", Cardiovasc Intervent Radiol, 33, pp.1168~1179 (2010)
112. Ganguli S, "Postembolization syndrome : changes in white blood cell counts immediately after uterine artery embolization", J Vasc Interv Radiol, 19, pp.443~445 (2008)
113. Casadaban LC, "Conventional ethiodized oil transarterial chemoembolization for treatment of hepatocellular carcinoma : contemporary single-center review of clinical outcomes", AJR Am J Roentgenol, 206, pp.645~654 (2016)
114. Shim JH, "Does postembolization fever after chemoembolization have prognostic significance for survival in patients with unresectable hepatocellular carcinoma?", J Vasc Interv Radiol, 20, pp.209~216 (2009)
115. Guo JG, "Novel multimodal analgesia regimen improves post-TACE pain in patients with hepatocellular carcinoma", Hepatobiliary Pancreat Dis Int, 17, pp.510~516 (2018)
116. Lu H, "Mechanism and risk factors of nausea and vomiting after TACE : a retrospective analysis", BMC Cancer, 21, pp.513~ (2021)
117. Lv WF, "Liver abscess formation following transarterial chemoembolization: clinical reatures, risk factors, bacteria spectrum, and percutaneous catheter drainage", Medicine(Baltimore), 95, pp.e3503~ (2016)
118. Arslan M, "Liver abscesses after transcatheter arterial embolization", J Int Med Res, 47, pp.1124~1130 (2019)
119. Lencioni R, "Modified RECIST(mRECIST)assessment for hepatocellular carcinoma", Semin Liver Dis, 30, pp.52~60 (2010)
120. Edeline J, "Comparison of tumor response by Response Evaluation Criteria in Solid Tumors(RECIST)and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma", Cancer, 118, pp.147~156 (2012)
121. Yamanaka K, "Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma", J Gastroenterol, 47, pp.343~346 (2012)
122. Park JW, "Consensus recommendations and review by an international Expert Panel on Interventions in Hepatocellular Carcinoma(EPOIHCC)", Liver Int, 33, pp.327~337 (2013)
123. Choi J, "Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma", PLoS One, 15, pp.e0229696~ (2020)
124. Rhee H, "Poor outcome of hepatocellular carcinoma with stemness marker under hypoxia : resistance to transarterial chemoembolization", Mod Pathol, 29, pp.1038~1049 (2016)

관련 논문AI추천